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OBJECTIVES: Fixed-dose combination formulations, which simplify the administration of drugs and prevent the
development of drug resistance, have been recommended as a standard anti-tuberculosis treatment regimen.
However, the composition and dosage recommendations for fixed-dose combination formulations differ from
those for separate formulations. Thus, questions about the effectiveness and side effects of combination
formulations remain. The aim of this study was to compare the safety and efficacy of these two types of anti-
tuberculosis regimens for pulmonary tuberculosis treatment.
METHOD: A prospective, randomized controlled study was conducted using the directly observed treatment
short-course strategy. Patients were randomly allocated to one of two short-course regimens. One year after
completing the treatment, these patients’ outcomes were analyzed. ClinicalTrials.gov: NCT00979290.
RESULTS: A total of 161 patients were enrolled, 142 of whom were evaluable for safety assessment. The two
regimens had a similar incidence of adverse effects. In the per-protocol population, serum bilirubin
concentrations at the peak level, at week 4, and at week 8 were significantly higher for the fixed-dose
combination formulation than for the separate formulations. All patients had negative sputum cultures at the
end of the treatment, and no relapse occurred after one year of follow-up.
CONCLUSIONS: In this randomized study, transient higher serum bilirubin levels were noted for the fixed-dose
combination regimen compared with the separate formulations during treatment. However, no significant
difference in safety or efficacy was found between the groups when the directly observed treatment short-
course strategy was used.
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’ INTRODUCTION
Tuberculosis (TB) is one of the major causes of death from a
curable infectious disease. The standard short-course treat-
ment for adult TB is a regimen of isoniazid (INH, H),
rifampicin (RIF, R), pyrazinamide (PZA, Z), and ethambutol
(EMB, E) for the two-month initial phase, followed by a four-
month phase of continuation of treatment with INH and RIF
or with INH, RIF, and EMB (if there are high levels of INH
resistance or if INH drug susceptibility testing results are
unavailable before the continuation phase begins)
(1). Despite the availability of effective anti-TB drugs, poor
drug adherence may lead to treatment failure and may
promote drug resistance. Additionally, inadequate doses may
also lead to treatment failure and to the emergence of drug
resistance if the anti-TB drugs are given in an unsupervised
manner (2). The use of fixed-dose combinations (FDCs) of
anti-TB drugs and a directly observed treatment short-course
strategy (DOTS), as recommended by the World Health
Organization (WHO) and other organizations, helps to ensure
adequate treatment (3–5). The efficacy, tolerability, and
acceptability of FDCs have been described in several studies
(6–8). Although FDC formulations simplify TB therapy,
current evidence does not indicate that these formulations
improve treatment outcomes among patients with active TB
(9). The dosages of the different FDC components are
therefore not consistent, so higher risks of drug toxicity and
adverse reactions should also be considered.
A previous study revealed that a three-drug FDC (3-FDC)
regimen resulted in fewer drug-related adverse events than
separate formulations (SFs) of anti-TB drugs did; however,
the study method was self-administered treatment and wasDOI: 10.6061/clinics/2015(06)08
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did not implement the DOTS (10). Additionally, the available
3-FDC formulation in Taiwan had a higher ratio of INH to
RIF and PZA. Since 2006, however, the DOTS has been fully
implemented in Taiwan. The aim of the present study was to
compare the adverse effects and efficacy of a short-course
regimen between an FDC and SFs of anti-TB drugs in the
treatment of pulmonary TB and to examine the benefits of
the DOTS.
’ METHODS
A prospective, open-label, randomized controlled study
was performed at E-DA hospital, which is a 1,000-bed
teaching hospital, from October 2008 to November 2009.
The study protocol was approved by the hospital’s
ethics committee (EMRP-097-081), and all involved partici-
pants signed informed consent forms. ClinicalTrials.gov:
NCT00979290
Eligibility criteria
Patients aged 18 years and older with suspected
pulmonary TB (at least two sputum specimens positive
for acid-fast bacilli [AFB] on direct smear microscopy or one
positive specimen and a chest X-ray or chest computed
tomography [CT] scan consistent with pulmonary TB), as
determined by a clinician, were initially included in the
study. The pulmonary TB diagnosis was confirmed histo-
logically, microbiologically, or based on improvements in
clinical status and imaging after completing the full course
of treatment.
Patients were excluded from the study if they had a history
of receiving anti-TB treatment, had a life expectancy of less
than six months, had abnormal baseline liver function (alanine
aminotransferase [ALT] or aspartate aminotransferase [AST]
values greater than three times the upper limit of normal
[ULN] and/or total bilirubin [BIL] values greater than 2 mg/
dL), or had received immunosuppressive treatment.
Study regimens
The patients were randomly and sequentially assigned to
either the FDC group or the SF group according to a
randomization table created using Microsoft Word 2007
software. The FDC group received Rifaters (Gruppo Lepetit
SPA, Lainate, Italy) and EMB (Veterans Pharmaceutical,
Taoyuan County, Taiwan) for the first two months, followed
by Rifinahs (Gruppo Lepetit SPA, Lainate, Italy) and EMB
for an additional four months or longer. The daily dosage of
Rifaters (INH/RIF/PZA: 80/120/250 mg per tablet) con-
sisted of three tablets for patients weighing 30–39 kg, four
tablets for patients weighing 40–49 kg, and five tablets for
patients weighing 50 kg or more. Meanwhile, the daily
dosage of Rifinahs consisted of three tablets of Rifinah
(150)s (INH/RIF 100/150 mg per tablet) for patients
weighing less than 50 kg and two tablets of Rifinah(300)s
(INH/RIF 150/300 mg per tablet) for patients weighing
50 kg or more. The SF group received INH (Genuine
Chemical Pharmaceutical, Taiwan), RIF (Swiss Pharmaceu-
tical, Taiwan), PZA (Pei Li Pharmaceutical Industrial,
Taiwan), and EMB for the first two months, followed by
HRE (INH, RIF, EMB) for an additional four months or
longer. The daily dosages of the SFs were selected based on
published recommendations (11,12). The HRE was adminis-
tered in the continuation phase because of a high prevalence
of primary resistance to INH and because approximately
25% of patients in Taiwan are diagnosed with pulmonary TB
based on their clinical presentation (13–15).
Sputum collection and culture methods
Sputum was collected from the patients at two and four
months of treatment and at the end of treatment. Three sets
of sputum samples were obtained at each collection time
point. The sputum specimens were expectorated by the
patients, and the standardized procedures for sputum
storage, sputum smear preparation, and acid-fast staining
were conducted in accordance with WHO recommendations
(16). All specimens were processed and cultured on Low-
enstein-Jensen medium using an MGIT 960 system. Drug
susceptibility tests were performed using the proportion
method with 7H10 medium. If specimen collection was
inadequate and culture results revealed contamination,
repeat specimens were collected.
Adverse effects and efficacy assessments
Clinical information was obtained from a questionnaire
provided to the patients during consultation or after
interviewing the patients’ family members. Adverse
effects, including symptoms and altered laboratory results,
were closely assessed at each visit during the first and
second weeks of the first month of treatment and were
then assessed monthly over the next four months.
Hepatotoxicity was defined as functional disturbance
(AST/ALT o3ULN and total BIL o3 mg/dL), hepatitis
(AST/ALT 43ULN with symptoms or AST/ALT 45
ULN and total BIL 43 mg/dL), or severe hepatotoxicity
(persistent hepatitis after re-challenge with INH, RIF, and
PZA and permanent modification of the anti-TB drug
regimen). Anti-microbial efficacy was assessed by mon-
itoring the bacteriological response rate (the negative
proportion) at two and four months and at the end of
treatment. The negative sputum proportion was defined as
the earliest time at which the sputum culture became
negative for TB, combined with the requirement that it
remain negative thereafter.
Treatment response was based on the WHO definition, as
follows (1). Cure was defined by a sputum smear or culture
that was positive at the beginning of treatment but negative
in the last month of treatment. Failure was defined by a
sputum smear or culture that was positive at five months of
treatment or later. Treatment completion was defined by
completion of treatment without fulfillment of the criteria to
be classified as either a cure or a failure. Treatment success
was defined as the sum of treatment cure and completion.
The assessment of relapse focused on the patients who
completed treatment and follow-up without interruption,
and relapse was defined as a positive culture at any time up
to one year after completion of treatment.
Patient populations and DOTS
The randomized patients who received at least one dose of
medication were considered as the intent-to-treat (ITT)
population. All ITT patients who had completed treatment
and one year of follow-up, who had received the correct
daily dosage and who had not violated the protocol in any
way that might influence the efficacy outcome were
considered as the per-protocol (PP) population. Additionally,
all patients randomized in the study who received at least
one dose of medication and who had at least one element of
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adverse effect information were considered as evaluable for
safety analysis. All patients were treated under the direct
supervision of health workers and were regularly followed
up at the clinic during treatment. The total duration of the
studied treatment was at least six months, depending on
the clinician’s evaluation. After completing treatment, the
patients were followed up for one year. Chest X-rays were
arranged at one, two, and six months during treatment and
at three, six, and 12 months after completion of treatment or
at any time when the patients presented with respiratory
symptoms. If any abnormalities were noted, sputum was
collected for AFB smear and culture.
Since 2006, the DOTS has been recommended by the
Taiwan CDC as the optimal treatment strategy (15). In the
current study, a trained supervisor observed the patient
during medication administration 5 days/week, whereas
weekend doses were self-administered. However, treatment
intake was still checked by the supervisor by unplanned
visits to patients’ homes and by pill counting (17).
Statistical analysis
The sample size was determined based on the reported
incidence of hepatitis induced by the SFs and by the same
anti-TB drug components in the form of an FDC (18,19). The
expected success rate in the SF group was estimated to be
80%. With a=0.05, P1=0.03, and P2=0.21, it was estimated
that 66 evaluable patients per group were included,
considering an expected drop-out rate of 20%.
Inter-group differences in demographic data, clinical
characteristics, diagnostic methods, drug-related adverse
effects, disease severity, and laboratory data were examined
using two-sided Fisher’s exact tests or chi-square tests for
categorical variables and independent-samples Student’s
t tests for continuous variables. Statistical software (SPSS
version 13.0; SPSS; Chicago, IL, USA) was used for all
statistical analyses. A p-value of o0.05 was considered to be
statistically significant.
’ RESULTS
Of a total of 210 patients who were diagnosed with
suspected pulmonary TB by physicians from October 2008 to
November 2009, 161 patients agreed to enroll in this study.
The enrolled patients were randomly assigned to either the
FDC group or the SF group, and both groups were treated
using the DOTS. The baseline demographic characteristics of
the ITT and PP populations are presented in Table 1. No
significant differences were found between the two groups in
terms of demographic or clinical characteristics. Diabetes
mellitus was the most common underlying disease. Of the
161 randomized patients, 63 were excluded from the analysis
for the following reasons: 32 had non-tuberculous mycobac-
teria (NTM) (19.9%), 14 died from non-TB-related causes
(8.7%), 12 were transferred to another hospital (7.5%), and
5 had resistant pathogens (3.1%) (3 with pathogens resistant
to INH and 2 with pathogens resistant to INH and
streptomycin). No significant difference was found between
the groups in terms of the reasons for exclusion from the PP
analysis (Figure 1).
A total of 142 patients were evaluable for safety assessment.
No significant differences between the two regimens were
found with regard to adverse effects (Table 2). The most
frequently reported symptoms were similar between the two
groups, including skin disorders (56.3% in the FDC group and
41.0% in the SF group), subjectively reported blurred vision
(46.9% in the FDC group and 47.43% in the SF group), and
peripheral neuropathy (39.1% in the FDC group and 30.8% in
the SF group). The most frequently reported system/organ-
related adverse reaction detected by laboratory examinations
was hyperuricemia (48 mg/dL: 89.1% in the FDC group and
89.7% in the SF group;413 mg/dL: 20.3% in the FDC group
and 23.1% in the SF group). Functional disturbance in hepatic
enzymes was more frequent in the FDC group (42.2%) than in
the SF group (39.7%), but this difference was not significant.
Moreover, one patient in the FDC group and one patient in the
SF group had severe hepatotoxicity that required permanent
modification of their anti-TB treatment regimen. Four patients
in the FDC group and two patients in the SF group required
unscheduled hospitalization because of adverse effects related
to the anti-TB treatment (three cases of hepatitis and one case
of drug-induced fever in the FDC group and one case each of
severe vomiting and urticaria in the SF group).
In the PP population, we analyzed liver function fluctua-
tion during anti-TB drug treatment. The results revealed that
serum total BIL levels at the peak level and at weeks four and
eight were significantly higher in the FDC group compared
Table 1 - Demographic and clinical characteristics of the study patients.
ITT PP
FDC Group SF Group p-Value FDC Group SF Group p-value
Patient number 75 86 49 49
Age (years), mean ± SD 59.2±16.7 64.9±17.2 0.04 57.8±17.2 62.3±17.3 0.23
BW (kg), mean ± SD 57.5±9.6 55.4±11.3 0.19 56.9±10.1 56.2±11.5 0.89
BMI (kg/m2), mean ± SD 21.0±3.2 23.2±4.4 0.41 20.6±3.3 20.8±3.5 0.79
Gender (male) 50(66.7) 59(68.6) 0.81 33(67.3) 35(71.4) 0.66
Co-morbid conditions
Diabetes mellitus 10(13.3) 14(16.3) 0.60 10(20.4) 14(28.6) 0.35
Hepatitis carrier (HBV/HCV) 11(14.7) 8(9.3) 0.29 10(20.4) 7(14.3) 0.42
COPD 4(5.3) 9(10.5) 0.23 2(4.1) 7(14.3) 0.16
Malignancy 4(5.3) 3(3.5) 0.57 3(6.1) 2(4.1) 1.0
Renal insufficiency 3(4.0) 3(3.5) 0.86 2(4.1) 2(4.1) 1.0
Alcohol consumption 13(17.3) 18(20.9) 0.56 8(16.3) 7(14.3) 0.78
Smoking 26(34.7) 32(37.2) 0.74 18(36.7) 19(38.8) 0.84
The data are presented as n(%) or as the mean ± standard deviation (SD). ITT=intent-to-treat; PP=per-protocol; FDC=fixed-dose combination;
SF=separate formulation; BW=body weight; BMI=body mass index; HBV=hepatitis B virus; HCV=hepatitis C virus; COPD=chronic obstructive pulmonary
disease; CXR= chest roentgenography; PCR=polymerase chain reaction
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with the SF group (p=0.03, 0.04, and 0.03, respectively)
(Table 3).
The severity of disease was not significantly different
between the two regimens (Table 4). In particular, 17 (34.7%)
patients in FDC group and 18 (36.7%) patients in the SF
group were sputum smear positive. After two months of
treatment, four patients (two in the FDC group and two in
the SF group) were smear positive. Only one patient in the
FDC group was still sputum smear and culture positive after
two months of treatment, whereas all other patients were
culture negative. The negative sputum proportion rate after
two months of treatment was 93.5% in the FDC group and
100% in the SF group. All patients in the FDC and SF groups
were sputum culture negative after four and six months of
treatment, respectively No relapse occurred in either group
after one year of follow-up.
’ DISCUSSION
FDCs, which simplify the administration of drugs and
prevent the development of drug resistance (20), have been
recommended as a standard anti-TB treatment regimen (4,5).
However, the composition and dosage recommendations for
FDCs differ from those for SFs, which is a major concern for
clinicians. We found that when treatment with anti-TB
medications was supervised using the DOTS, the incidence
rates of adverse effects and efficacy were not significantly
different between the FDC and the SF regimens in a safety
population analysis. Only the occurrence of transient
hyperbilirubinemia was significantly different in the patients
treated with the FDC regimen compared with those treated
with the SF regimen during the course of treatment in the PP
population.
In the current study, the negative sputum proportion rate
after two months of treatment was 93.5% for the FDC
regimen and 100% for the SF regimen, which are values
comparable to those in previous reports (10,19,21). No
treatment failures after six months of treatment and no
relapse after one year of follow-up were observed for either
regimen. The treatment success in this study is comparable to
that in previous reports (10,19,22). In fact, nearly all work
comparing the efficacy of FDCs and single-drug regimens
has reported similar results (i.e., no significant differences),
regardless of the FDC formulation, when patients were
enrolled in DOTS-based studies (23).
Comparisons of safety between FDC and SF regimens
have been reported in previous studies, and most rando-
mized studies have revealed that adverse events did not
significantly differ between the groups (24,25). In contrast,
Su et al. (10) reported fewer drug-related adverse events
among patients receiving an FDC regimen compared with
an SF regimen; however, the study was not supervised
using the DOTS, and the dosages of the components of
Rifaters were different from those of the current FDCs in
Taiwan. Additionally, the recommended dosage of Rifaters
based on body weight is higher than the recommended
dosage of INH (e.g., 400 mg/day vs. 300 mg/day in 50 kg
patients, which is higher than the maximum of 300 mg
daily), so the higher dosage of INH in those receiving FDC,
which has a greater risk of inducing liver dysfunction,
should be considered. In the current study, we found that in
the PP population, the average peak levels of AST, ALT, and
total BIL in the patients receiving the FDC regimen were
higher than those in the patients receiving the SF regimen
during the course of treatment. However, hepatotoxicity
(including functional disturbance and severe hepatotoxi-
city) did not significantly differ between the two regimens
in the safety population study. Cholestasis is thought to be
an adverse effect of RIF treatment that may be insidious and
that may be resolved without discontinuing the drug (26).
The combined use of RIF and INH has been reported to
pose an increased risk of hepatotoxicity (27), which may
explain the transient, statistically significant hyperbilirubi-
nemia observed in the FDC group (receiving a higher
dosage of INH) compared with the SF group in the present
study.
In the current study, the mean age of the enrolled patients
was approximately 60 years. The safety evaluation among
these patients was based on symptoms and laboratory
examinations. The major adverse effects were skin reactions,
overall hepatotoxicity, and non-symptomatic hyperuricemia.
However, no significant differences were found between the
two study groups. However, a higher occurrence of adverse
effects was observed in this study compared with other
studies (28), which may have been due to differences in the
age and ethnicity of the study populations (15).
Figure 1 - Study profile. ITT=intent-to-treat; PP=per-protocol;
NTM=non-tuberculous mycobacteria; FDC=fixed-dose combina-
tion; SF=separate formulation
Table 2 - Adverse effects in the patients evaluable for safety.
FDC Group SF Group p-value
Total patients 64 78
Symptoms
Arthralgia 13(20.3) 19(24.4) 0.56
Peripheral neuropathy 25(39.1) 24(30.8) 0.30
Skin disorders (rash, itching) 36(56.3) 32(41.0) 0.07
Blurred vision 30(46.9) 37(47.4) 0.95
Gastrointestinal disorders
(anorexia, nausea, vomiting)
17(26.6) 20(25.6) 0.90
Fatigue 14(21.9) 15(19.2) 0.69
Systemic organ laboratory reaction
Hepatotoxicity 0.87
Functional disturbance 27(42.2) 31(39.7)
Hepatitis 6(9.4) 5(6.4)
Severe hepatotoxicity 1(1.6) 1(1.3)
Hyperuricemia
48 mg/dL 57(89.1) 70(89.7) 0.89
413 mg/dL 13(20.3) 18(23.1) 0.69
Thrombocytopenia (o150 103/L) 12(18.8) 12(15.4) 0.59
Leukopenia (o3.5 103/L) 5(7.8) 5(6.4) 0.74
Unscheduled hospitalization 4(6.3) 2(2.6) 0.28
* The data are presented as n(%). FDC=fixed-dose combination;
SF=separate formulation
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FDC treatment has the advantages of increased acceptance
and adherence, an increased success rate, a lower cost, and
increased prevention of prescription errors and drug
resistance (6,10,19,20,24). These benefits are based on patient
adherence to treatment. Indeed, previous studies have
suggested that when the DOTS is deficient, the increased
adherence that is expected with an FDC regimen may
compensate for the small difference in efficacy between SF
and FDC regimens (23,24). In the present randomized study,
FDC and SF regimens were objectively compared using the
DOTS standard, and the results revealed that the potential
disadvantages of SFs appeared to be overcome if TB patients
are treated using the DOTS.
Based on the higher price of FDCs at current market
rates in Taiwan, we estimate that the cost of an FDC-based
regimen (233 US$) is approximately 1.7 times higher than
that of an SF regimen (135 US$) for a six-month treatment
course. These estimated costs must be carefully inter-
preted because they only include the product cost and
were determined based on standardized DOTS programs.
These findings differ from those in previous reports,
which predicted that FDC prices will drop as competi-
tion and production volume increase (4,29). In resource-
limited countries, DOTS-based programs have not
been successfully implemented for TB care (30), but
the use of FDCs is likely to play a relevant role in
increasing cure rates and also in decreasing the cost of
managing the drug supply system due to simplification of
formulations, ordering, procurement, distribution, and
storage (31).
There are certain limitations to the present study. First, the
prevalence of NTM is increasing in Taiwan (32), and the fact
that the clinical presentation of NTM was difficult to
differentiate from that of TB at initial enrollment resulted
in nearly 20% of the patients being excluded from the
analysis. Second, more elderly TB patients were included in
this study compared with other studies (22,28), and their
higher rates of co-morbidities may have influenced their
ability to complete the one year of follow-up. Third, patients
with drug-resistant strains were also excluded to avoid the
influence of efficacy assessment between regimens. All of
these factors limited the number of cases that were analyzed
at the end of the study, which could have led to these
findings being inconclusive. However, although only few
patients who completed this study were analyzed, the
patients included in the analysis had multiple underlying
diseases that are typical in daily clinical practice. In any case,
a larger randomized study is warranted to confirm the
findings of this study.
In conclusion, the present study demonstrated that DOTS-
based TB treatment with an FDC or SF regimen shows no
significant differences in terms of efficacy or adverse events.
Although the components of the FDC and their recom-
mended dosages were not consistent with those for SFs of
anti-TB drugs, only transiently increased serum levels of BIL
were noted in the FDC group.
Table 3 - Liver function tests in the PP population during anti-TB drug treatment.
FDC Group (n=49) SF Group (n=49) p-value
Baseline AST level (U/L) 31(28–56) 23(18–37) 0.6
Peak AST level (U/L) 67(45–102) 55(33–60) 0.86
1st week 35(23–43) 24(19–31) 0.83
2nd week 36(28–57) 27(24–37) 0.41
4th week 38(21–43) 30(25–49) 0.42
8th week 36(31–57) 30(25–58) 0.41
12th week 33(29–54) 29(25–37) 0.93
16th week 40(29–45) 25(23–36) 0.20
Baseline ALT level (U/L) 20(17–41) 18(14–30) 0.79
Peak ALT level (U/L) 63(46–97) 46(26–102) 0.41
1st week 16(11–35) 15(12–26) 0.65
2nd week 24(17–66) 19(16–37) 0.19
4th week 21(16–37) 26(21–44) 0.93
8th week 23(19–46) 28(19–62) 0.55
12th week 39(20–47) 33(21–58) 0.97
16th week 24(21–39) 23(16–27) 0.26
Baseline T-BIL level (mg/dl) 0.85(0.59–.093) 0.6(0.45–1.22) 0.22
Peak T-BIL level (mg/dl) 1.21(0.98–1.54) 0.93(0.73–1.29) 0.03
1st week 0.76(0.55–0.99) 0.61(0.43–0.7) 0.28
2nd week 0.64(0.42–0.82) 0.66(0.36–0.84) 0.11
4th week 0.87(0.66–1.10) 0.72(0.57–0.89) 0.04
8th week 1.06(0.70–1.43) 0.57(0.44–0.97) 0.03
12th week 0.89(0.54–1.15) 0.77(0.46–1.07) 0.21
16th week 0.95(0.76–1.21) 0.65(0.47–1.08) 0.15
The data are presented as the median(range). AST=aspartate aminotransferase; ALT=alanine aminotransferase; T-BIL=total bilirubin; FDC=fixed-dose
combination; SF=separate formulation
Table 4 - The severity of disease and the distribution of
diagnostic methods.
FDC Group (n=49) SF Group (n=49)
Severity of disease
Cavitation on CXR 8(16.3) 5(10.2)
Smear positive 17(34.7) 18(36.7)
Diagnosis
Culture 29(59.2) 34(69.4)
Pathology 1(2) 0
PCR 1(2) 0
Clinically diagnosed 18(36.7) 12(30.6)
* The data are presented as n(%). FDC=fixed-dose combination;
SF=separate formulation; CXR=chest roentgenography; PCR=polymerase
chain reaction
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